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Citation 
 
“The pathologies that damage the human brain are rarely restricted to single 
anatomical structures. Stroke, trauma and particularly degenerative diseases do 
not respect functional anatomical boundaries. But there is much to be learned 
from observation of what occurs in humans whose brains are damaged by such 
insults” [1]. 
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Populärvetenskaplig sammanfattning på svenska 
 
 
Medicin studerande: Safaeldin Amin 
Handledare: Marie Kalm 
 
Kan immunbrist påverka uttrycket av APP och thalamusstrukturen efter strålbehandlingen 
mot den omogna hjärnan 
 
Hjärntumörer är ovanliga hos barn men ändå utgör en tredjedel av all barncancer i västvärlden. 
Lyckligtvis kan mer än 70 % av dessa hjärntumörer botas med strålbehandling ofta i 
kombination med cellgiftbehandling och/eller operation. Strålbehandling är en effektiv metod 
vid behandling av barn med hjärntumörer, men ger förutom akuta även svåra kroniska 
biverkningar. Nedsatt kognitiv funktion är ett exempel på en sådan biverkan som kan försämra 
barnets livskvalité livet ut. De kroniska biverkningarna tros bero på den akuta inflammationen 
som stör hjärnans normala aktiviteter bl. a. minnets funktioner. Drabbade barn får då t.ex. 
inlärningssvårigheter. 
En viktig del av immunförsvaret är det medfödda immunförsvaret som spelar roll i 
nervssystemets utveckling under både fosterutvecklingen och barndomen. Tidigare studier har 
visat att möss som saknar del av det medfödda immunförsvaret och som genomgår strålterapi 
haft bättre inlärningsförmåga jämfört med möss med bevarad komplett medfödd immunförsvar 
och som också genomgår samma strålterapi. Varför? Man har visat att strålterapin orsakar en 
inflammatorisk reaktion med massiv nervcelldöd. Vidare studier kunde man inte koppla 
förbättringen av inlärningsförmåga till limbiska systemet. Med detta projekt vill man undersöka 
om denna förbättring kan beror på någon del av mellanhjärnan istället. 
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brain? 
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Abstract 
Brain tumours in children preserve certain characteristics of the original stem cells that develop 
during foetal life. How do cancer cells acquire these characteristics is unknown. New research 
suggests that cell origin and its genetic alterations play a huge role in tumour development, 
tumour aggressiveness and prognosis. It is well known that more than 70 % of brain tumours 
in children can be cured with cranial radio-therapy (CRT) in combination with chemotherapy 
and/or surgery. Thereby, CRT is an effective cornerstone of the treatment of paediatric brain 
tumours but it also causes severe chronic adverse effects, such as neurocognitive decline. It is 
believed that CRT causes acute neuro-inflammation that making it difficult for the brain to heal 
and thereby disturbs the plasticity of the brain. 
C3 is an influential component of the complement system. Several previous studies highlighted 
the importance of C3 in both foetal and adult neurogenesis as it has an immune-dependent 
ability to protect/repair damaged cells and removal of damaged synapses in the brain. It has 
also been shown that mice lacking C3 have a better cognitive outcome following cranial radio-
therapy (CRT). The part of the brain called the thalamus is a collection of relay stations with 
extraordinary function between the senses in our body, and our reaction to these senses via the 
cortical and subcortical brain and it rich in APP-cells. Amyloid precursor protein (APP) is an 
integral membrane protein expressed in many tissues, including the thalamus. APP has been 
shown to have an important role as a regulator of synapse formation and modulation of neural 
plasticity (memory and learning ability). 
This project used wild type mice and mice lacking C3 to highlight how CRT will affect the 
thalamus and its synaptic functions. Also, four groups were used in this study; control wild 
type, CR-treated wild type, control C3-genmodified and CR-treated C3-genmodified (C3-/-) 
mice. Significant reduction in the volume of the thalamus was noted following CRT in both 
wild type and C3-genmodified mice. The expression of APP in the thalamus appears to be 
preserved in spite of CRT in both wild type and C3-genmodified mice. We conclude that 
modulating the immune system did not protect the thalamus from CRT-induced injury. In 
addition, C3-defiicency (C3-/-) did not alter the APP expression in this region. The protection 
of memory function seen in C3-deficient (C3-/-) mice after CRT must therefore depend on 
another region in the brain. 
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Introduction 
Each year, nearly 70 children develop a serious brain tumour in Sweden. Most of these children 
survive at least five years after radiotherapy treatment [2,3]. However, many live with motor 
and intellectual disabilities [3]. Cranial radio-therapy (CRT) aims to cure children with brain 
tumours with as few side effects as possible and to get them an optimal quality of life 
afterwards. It has been shown that Cranial radio-therapy damages both tumour cells and normal 
cells in the brain (for example oligodendroprecursors, stem cells and microglia) [4-6]. This 
CTR-induced injury leads to different neurotoxic processes that are possible to measure in the 
cerebrospinal fluid (CSF) [7]. Beside the cell death that CTR generates, it has also been shown 
to negatively influence the chemical milieu of the brain. After CRT, inflammation is the 
unavoidable process to remove dead and injured cells. Furthermore, a chronic inflammatory 
response after CRT could affect the healing of the brain negatively. The challenge is to optimize 
radiotherapy, to make injury to normal cells as little as possible, and to provide an opportunity 
to restore as so much normal activity as possible in the brain, without compromising cancer 
treatment. 
 
Paediatric brain tumours – PBT 
Every year there are about 300 children in Sweden who get some type of paediatric cancer. It 
is often a severe and aggressive disease [2, 8, 9]. In general, children cancers have an embryonic 
origin such as neuroblastoma and glioblastoma. Therefore, it has been suggested that both 
environmental factors and hereditary factors tend to be involved in different degrees in the 
development of these rare tumours. However, the cause of the majority of paediatric CNS-
tumours is still unknown. Leukaemia and lymphoma are the most common cancer forms in 
children representing around 42% of the cases, while brain, spinal tumours and solid tumours 
(blastomas and sarcoma) correspond to 25-31% each [2, 8, 10] (figure 1). The incidence of 
childhood cancer and the disease panorama is age related. In the USA, many paediatric brain 
cancers are diagnosed in the first 4 years of life, the most common being astrocytoma [10, 11] 
(figure 2). Different incidence rates have been reported from different parts of the world [8, 10, 
12].  
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Figure 1 Incidence of cancer in childhood (up to the age of 19 years). CNS cancer represents 
18.7-25.4 % and this is age-related [13]. 
 
 
 
Figure 2 Age-related incidence rates for common CNS tumours, United States, 2006 to 2010. 
Astrocytoma is the most common brain cancer of childhood in USA [8]. 
Figure 1 
Figure 2 
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Childhood brain cancer can anatomically and radiologically be subdivided in supra- and 
infratentorial. Supratentorial and infratentorial tumours occur overall in nearly equal frequency 
but supratentorial are more common in children < 2 years, whilst infratentorial are more 
common in the ages 4-10 [9, 12]. As for embryonic CNS tumours, they are distributed evenly 
between the different age groups. Most childhood cancers are primary tumours and their 
aetiology is mostly unclear, but they may be associated with certain diseases which have genetic 
aetiology; for example, neurofibromatosis and Li-Fraumeni Syndrome. As for the anatomy, in 
comparison to adult brain tumours, paediatric brain tumours are mostly localized in the 
posterior fossa and display diversity in their patho-histological features (cellular genesis and 
cellular biology). For this reason and to facilitate specific diagnosis, therapy and prognosis of 
brain tumours, the different types are subdivided into several grades – WHO 2007 
classifications, where grade I is almost benign and grade 4 is the most aggressive types – 
anaplastic with poor prognosis [9, 12, 14]. Astrocytic tumours are the most common 
neuroepithelial tumours and mostly affect the cerebellum or hypothalamic/optic tracks [9, 12]. 
 
Brain cancer therapy 
Recent studies have shown that the survival rates of children with paediatric brain tumours have 
arisen during the last few decades (figure 3) [2, 12]. The survival rate of CNS-tumours in 
children has increased dramatically since 1951. CRT, chemotherapy and surgery have played 
essential roles in the therapy of this group of tumours. For best reduction of long term morbidity 
and to achieve optimal survival, this multidisciplinary neuro-oncological approach plays an 
important role. 
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Figure 3 shows the different survival rates after paediatric cancer therapy between 1951 and 
2010 [2]. CNS paediatric patients had a better chance of survival in the years 1951- 1965 when 
multiple modalities of therapy started being used. In 1965 chemotherapy took a more 
dramatically important place but CRT remained the first therapy modality. 
 
 
Figure 3 
 Chemotherapy 
 Irradiation 
 Surgery 
S
u
rv
iv
a
l 
in
ci
d
en
se
n
s 
10 
Chemotherapy 
Chemotherapy is a limited treatment method, thereby different types are given to cure CNS 
cancer or to limit and slow down cancer progression. Chemotherapy can also be used to relieve 
symptoms when a cure isn´t possible. In some cases, and under certain circumstances, it is 
recommended to use chemotherapy to reduce the risk of recurrence, known as adjuvant 
treatment. Such therapy is standard after some surgeries, such as breast- or colon cancer-
surgeries. Many pharmacological studies first aim to adjust or make more effective choice of 
doses and types of chemotherapy so that side effects and damage to normal cells will be as 
minimal as possible, while the effect on the tumour becomes optimal [15-20]. Therefore, such 
chemotherapy treatment is different from the traditional therapy. Chemotherapy agents such as 
nitrosoureas, platin compounds and nitrogen solutions bind selectively to target tumour cells 
reacting with DNA, RNA and -molecular polypeptide’s receptors thereby helping healthy cells 
to repair themselves and survive to a greater extent, and thereby the risk of side effects would 
be reduced. Side effects extend from renal to transient hepatotoxicity for nitrosoureas; nausea, 
vomiting and hypersensitivity reactions for platin compounds; and syndrome of inappropriate 
anti-diuretic hormone secretion (SIADH), infertility and myelosuppression for nitrogen 
solutions [15, 21]. 
Neurosurgery 
Neurosurgery is an essential cornerstone in neuro-oncology but it is highly dependent on 
tumour localization in the brain and its accessibility for surgery. Another important factor to be 
considered is the risk of different forms of surgery related disabilities, such as paralysis, and 
this must be accepted before proceeding. The prognosis of medulloblastoma and glioma is 
correlated with the extent of resection and the response for adjuvant chemotherapy [15, 21, 22]. 
In some cases, surgery is not the best option and treatment with either CRT or chemotherapy 
or both is used instead, as the case for low grade tumours [22, 23]. The postoperative 
complications of brain tumour surgery are approximately 10 % while the mortality rate is 
thought to be in the range of 0-20 % [23-25]. Diverse factors influence the outcome of childhood 
brain tumour surgery such as the child’s age, health condition, the type of tumour and its grade 
[24-26]. The major complication after neurosurgery include epilepsy, mutism, ataxia and 
speech abnormalities [25, 26] while endocrine complications include severe conditions as 
diabetes insipidus and hypocortisolism [25, 26]. 
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Cranial Radio-therapy (CRT) 
Cranial radio-therapy is an advanced cornerstone of the treatment of childhood brain tumours 
and it involves the use of ionizing radiation for cancer and some other conditions or diseases 
[4, 6]. Generally, it’s known that radiation transforms water molecules to chemically reactive 
hydroxyl ions that damage DNA and cell nuclei repair systems of both normal and cancer cells. 
Radiation therapy is given to many kinds of cancer patients, some of which are cured by it [27-
29]. Recently the therapeutic IR has been given through the use of particles; electrons (e-) or 
photon energy, protons (p+), and neutrons (n) [30, 31]. Electrons or electron beam is produced 
by a Linac; a linear accelerator, often used in the treatment of brain malignancies but used more 
frequently in craniospinal therapy [30, 32]. Photon energy or X-rays in range of 4-18 MV 
produced by a medical linear accelerator (Linac) is often used in radiotherapy of childhood 
brain tumours [31, 33]. Delivered CRT range of about 6 MV photons pass through the brain to 
induce the max effect on the tissue in question in order to achieve the best cure [7]. Radiation 
reactions in the body will certainly vary both in range and in intensity, and are often seen from 
2-3 weeks after the first treatment session (in humans a total dose of 20-30 Gy delivered as 2 
Gy per fraction) [4, 7, 34].  
In recent years, attention has been drawn to the increased risk of secondary malignancies and 
the neurocognitive effects of CRT on the brain, especially in infants and small children. 
Lifelong late effects are neurocognitive decline such as decline in IQ, attention deficits, 
depression, anxiety, antisocialism, inattentiveness, slowness of executive function, reduced 
ability of judgment and insight and somnolence (after partial CRT) [35-37]. These can be 
correlated to the histopathologic changes that affect both pathological and normal tissue such 
as demyelination and necrosis of normal cells. 
Another common adverse effect of cranial radio-therapy for brain tumours is the loss of one or 
several hormones. The brain of prepubertal children is more sensitive to CRT than adults, 
primarily because they are developing and growing. It can also lead to different degrees of 
hypopituitarism. Uncommon side effects induced by CRT are visual and hearing impairments 
that have a destructive influence on the quality of life of affected children [38, 39]. All the side 
effects are dose-dependent and the fractionation of CRT is an extremely important factor that 
seems have a reductive effect in almost all types of cranial radio-therapy [40]. 
The basic radiobiological effects of CRT-photons are DNA base damage, DNA-protein cross 
linking, and single and double stranded DNA breaks. CRT interacts with target cells in question 
directly or indirectly by free radicals and all these can be associated with a cascade reaction 
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leading to cancer cell death [5]. CRT kills the tumour effectively despite sub-lethal injures to 
normal tissues whilst using chemotherapy in combination takes care of micro-metastases [41-
43]. The acute side effects of cranial radio-therapy that might be experienced by the children 
vary and some of them are treatable. Many precautions are taken to treat the acute side effects 
before they occur, for example medications such as anti-nausea and steroids (Table 1) [44, 45]. 
There is still a complexity in understanding late effects of radiation therapy. It can be affected 
by the type of tissue which is treated, fraction size, quantity and quality of the fractions, total 
dose or fractions dose, and total treatment course. Such limited CRT therapy leads to significant 
reduction of normal brain tissue injury. Others factors which affect and confound the 
complexity in the understanding of late effects is related to the patient's general condition such 
as the patients’ age, comorbidities (especially genetic diseases such as neurofibromatosis type 
2) and previous CRTs [46-49]. 
Table 1 Common acute and subacute side effect after CRT to paediatric brain tumours. Some 
can be totally cured. 
 
Skin: Erythema, hyperpigmentation and hair loss. 
CNS: Headache, vomiting and nausea. 
Eye and Ear: Non-infectious conjunctivitis. Serous otitis media. 
Parotid: Acute parotiditis. 
Haematological: Leucopoenia and anaemia. 
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The complement system- C3 and C5 - role in the immune system 
 
The complement system, which C3 is part of, has been considered for a long time to be a 
humoral branch of the immune system, being responsible for recognizing, phagocytosis, 
cytolysis, and elimination of cellular debris and residues [50]. Additionally, it helps to sanitize 
the nerve system via microglia mediated mechanism that removes insulated and inaccurate 
synapses during brain development before adulthood [51-53]. There are many cell types in the 
brain which generate and express receptors responding to complement agents; microglia, 
astrocytes and others cells [54, 55]. All these cells are able to synthesise or express vast majority 
of the proteins (> 40 proteins) of the complement system [56, 57]. It is also well-known that the 
complement system is engaged in the innate immune system and has a central role to promote 
an inflammatory response both to reduce further damage to the tissue and to eliminate the 
pathogenicity of the injury mechanisms. When the C3 system is activated, it is converted to 
C3a by different enzymes that induces increased concentration of intracellular Ca+2 and even 
elevated expression of neutrophin in vivo. Thereafter, C3a manages the development of neural 
progenitor cells in the brain but other functions have also been shown. C3a is a small peptide 
with anaphylatoxic properties [58, 59].  
 
Both C3a and C5a are generated via proteolytic cleavage of C3 and C5, respectively. Both C3a 
and C5a have potentially anaphylactic and chemoattractant profiles when they bind to specific 
receptors via a cascade of protein cleavage and activation [60-62]. Moreover, C3a is more 
selective and has anti-inflammatory effects while C5a is thought to have a wide range of pro-
inflammatory effects (figure 4) [63-66]. This procedure ends with a collection of a membrane 
attack complex (MAC) that acts in variety of ways leading to either apoptosis of the cells or 
inducing an inflammation. This type of complement activation via C3a and C5a triggers the 
removal of damaged and unsuitable synapses, and encourages basal neurogenesis and ischemia 
induced neurogenesis [52, 67]. 
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Figure 4 shows a representative outline of the three complement activation pathways depending 
on factor’s stimulation. The alternative pathway activates C3 via activating surfaces, the lectin 
pathway activates C3 via sugar residues found on the pathogens and the classical pathway via 
antigen-antibody complex. C5L2 is “A controversial receptor of the complement 
anaphylatoxin, C5a” [5, 7, 68, 69]. 
 
 
In recent years, it has been shown that the complement system is involved in tissue regeneration 
in, for example, limbs of amphibians and liver regeneration of mammalian but how, remains 
unclear [70, 71]. Adult mice lacking C3 have been shown to be associated with retro-cognition 
ability after brain injury and even do not show signs as spontaneous epileptic activity in the 
hippocampus. The mechanism behind this is suggested to be related to the regulation of 
excitatory glutamatergic synapses and entails enhanced spatial learning [58, 72]. This reflects 
Alternative 
Pathway 
Classical 
Pathway 
Lectin 
Pathway 
C3 
Terminal Complement 
Complex (TCC) 
MBP, MASP  
C4, C2 
C1, C4, C2 
C3, Factor D, 
Factor B 
C5b, C6, C7, C8, C9 
C3b 
C3a 
C5a 
C3aR 
C5aR 
C5L2 
Figure 4 
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that C3 has a crucial role in synaptogenesis and neural plasticity. However, other studies have 
shown that in children who lack C3 activity or when the expression of the complement is 
deranged or incompetent, this increases susceptibility to harmful conditions such as 
meningococcal meningitis [73, 74]. Therefore, much research has suggested that the 
complement system’s polypeptides mainly provide protection against infections. Mice lacking 
C3 system are incapable of generating C3a and C5a, and therefore are unable to have basal and 
ischemia induced neurogenesis [67]. Other studies have shown that C3 affects the mount of 
synaptic loss during aging. Therefore C3-/- mice prove to be more protected and thereby have 
better hippocampal cognitive performance [72, 75]. 
 
When mice are treated with CRT, it can induce an inflammation which is believed to affect the 
decline and the differentiation of neural progenitor cells. Six hours after CRT, C3-/- mice had 
an increased inflammatory response such as increased levels of IL-1β and IL-6 but this did not 
occur in control mice [76]. Furthermore, one study showed that C3a manages the development 
of neuronal progenitor cells in the brain [77].  
 
Many CNS cells including microglia, astrocytes and nerve cells are able to produce the majority 
of the complement proteins. When brain tissue is injured, for example by CRT, it may activate 
the complement system, including C3, in the injured area [78]. Yet C3 activation is associated 
with neuronal loss after cerebral injures and in the long term helps neural protection and tissue 
healing [79], neural differentiation and migration of neural progenitor cells [77], and migration 
of hematopoietic stem or progenitor cells [80]. One aim of this study is to investigate why C3-
deficint mice have better learning and memory after treatment with CRT compared with control 
mice [76]. Marie Kalm et al. have shown that the hippocampus was not protected from CRT-
induced injury long-term, measured as stem cell survival [4, 76]. Therefore another region, the 
thalamus, can be involved in the memory process and was therefore investigated in this study 
(figure 5).  
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Figure 5 shows how the interaction between different parts of the brain involved in the memory 
process occurs. The fornix and mammillary bodies act as connections between the hippocampus 
and thalamus [81]. 
 
Thalamus 
The brain is still an extremely fascinating part of the body despite all years of research using 
high technologic methods. It is still a mystery. The area of interest in this thesis is the 
diencephalon, and more exactly the thalamus.  
The diencephalon includes the epithalamus, subthalamus, hypothalamus and thalamus. These 
are formed by the alar plates. The alar plates form three parts that have been described as 
neuromeres (prosomeres), which are similar to the rhombomeres of the hindbrain. Firstly, the 
rostral neuromere will form the prethalamus and hypothalamus. Secondly, the middle 
neuromere will form the thalamus and epithalamus. Lastly, the caudal neuromere will form the 
pretectum [82, 83].  
Cerebral Cortex
Previously formed memories
are thought to be stored in the
Hippocampus
is believed to have a critical role
in the formation of new memories.
Thalamus
Areas of the thalamus are
considered to have a role in the
formation of new memories partly
through their connections with the
hippocampus, and partly because
the thalamus is considered to be
important for mental alertness.
Figure 5 
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The thalamus is connected to both the hippocampus and cerebral cortex and thereby affects 
cognitive function and memory (figure 5) and it consists of approximately 50-60 nuclei (figure 
6) [84, 85]. It is considered to be the gateway to the cerebral cortex. This gateway has a critical 
role for spreading input to brain areas that influence cognitive functions, such as the neocortex 
and hippocampus. The human thalamus has two symmetrical parts affiliated with each other by 
connections intermedia and separated by the third ventricle. The nuclei in the ventral thalamus 
consist of the zona increta, the nucleus reticulare and nucleus pregeniculate. The nuclei in the 
dorsal thalamus consist of the allothalamic part even so called intra laminar nuclei and 
isothalamic part within subdivision parts. These nuclei have straight communications with the 
cerebral cortex except for nucleus reticularis and the allothalamic parts. The thalamus has many 
known but also unknown functions. Well-known functions are somatosensory, motor, 
consciousness, attention and neurocognitive (e. g. language and memory). Thalamic nuclei 
might have both contralateral and ipsilateral connections to the other parts of brain [86, 87]. 
 
 
 
Figure 6 shows the most studied nuclei of the thalamus of human brain [88]. The nuclei have 
various connections to other parts of the brain. For example, the cortex, hippocampus and basal 
ganglia. 
 
Figure 6 
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Amyloid Precursor Protein - APP 
APP is substantially expressed normally in the brain and even in other parts of our body and it 
has different isoforms (APP695, APP751 and APP770) which are expressed in various proportions 
[89]. APP is suggested to have neurotrophic properties and acts as an neuroprotective actor 
where it enhance synaptogenesis, memory formation, survival, outgrowth of the neuronal-cells 
and neurite outgrowth in both the cortex and hippocampus. APP even has antagonistic effects 
as neurotoxic Aβ [90-92]. The study by Kalm et al. demonstrated that the levels of CSF- 
sAPPα/β were reduced, 3 and 12 months after prophylactic CRT in patients with SCLC (small 
cell lung cancer) [7]. Therefore, there is interest to explore the role of APP in the brain, more 
precisely in the thalamus. APP is an important transmembrane protein and is expressed in large 
amounts in the brain [93, 94]. APP may function as a receptor with a key role in many cellular 
mechanisms [95, 96]. Its intracellular part is small while its extracellular part is much larger in 
spite of the fact that this small domain acts as receptor [97]. APP is cleaved via sequential 
proteolytic procedures and various metabolites can be obtained. In general, the cleavage of APP 
peptides generates and releases an extra cellular form of soluble APPα/β peptides [98, 99]. Also, 
the rest of APP is a membrane bound C-terminal fragment which includes a transmembrane 
and a short cytoplasmic peptide part called C99/C83. In the Amyloidogenic pathway, the APP, 
cleaved by β- following by γ-secretase, results in the production of an extra cellular sAPPβ and 
Aβ and an intra cellular domain ACID. AICD has been suggested to operate as a transcriptional 
regulator. sAPPβ is less active but even suggested to play a role in normal neural development 
and neuroprotection of developed CNS. Aβ in small aggregates is believed to cause cell 
membrane disturbance [100, 101] and in large aggregates is associated with Alzheimer’s 
disease [100, 102].  In other conditions such as Lewy body dementia, there is excess 
accumulation of neurotoxic substances in the CNS [100, 101, 103, 104]. 
In the Non-amyloidogenic pathway, APP can be cleaved by α-secretase following by γ-
secretase to form sAPPα released in the extra cellular matrix and p3 and ACID released in the 
cytoplasmic space. sAPPα is essential for learning and memory, synaptic transmission, axonal 
transport, and cell proliferation. sAPPα has many fold potency in terms of neuroprotective 
properties such as spatial memory performance and neural survival than sAPPβ does [105].  
Other types of APP isoforms cleaved by other caspases leads to the accumulation of various 
APP metabolites in the intracellular space [106, 107].  APP as a polypeptide is composed of 
nearly 700 amino acids and its gene transcription has been investigated in the human brain and 
it could also be found in PNS (peripheral nervous system) and skeletal muscles [108-110]. 
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Other analyses of cDNA of APP disclosed that at least four kinds of mRNAs originated via 
alternate splicing of exons [97, 111] and the product is named after its number of amino acids. 
For example, APP 751 or APP 770 due the spicing of exons 7 and 8 but other splicing alternative 
was established [111-113]. Aβ is a short peptide that contains between 37 to 49 amino 
acids residues and its region is suggested to be localized in the EC- and transmembrane domains 
(figure 7) [114]. 
 
 
 
Figure 7 Shows the processing of the amyloid precursor protein (APP) by α-, β- and γ-secretases. Here 
we find two pathways (β/γ or α/γ) of APP proteolysis. APP can be cleaved by either α- or β-
secretase, which is then followed by γ-secretase cleavage [103, 115]. 
 
  
Figure 7 
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Purpose 
Our main goal is to reduce injury to normal tissue following cranial radiotherapy, to improve 
cognitive function, and to promote recovery in patients, especially children, who survived brain 
tumours. 
Scientific issue: 
To test the hypothesis that modulating the complement system during and after radiotherapy 
can prevent damage in the thalamus and potentially affect the expression of APP. 
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Material and Methods 
Animals - Male and female mice 
We have investigated CRT-induced injury in control (WT- C57BL/6) and C3-deficient mice 
(backcrossed on C57BL/6 - Charles River Laboratories, Sulzfeld, Germany). All mice were 
bred in-house. Mice were maintained on a 12-hour light cycle with food and water provided 
“ad lib”. All mice were anesthetized with isoflurane and implanted with micro-transponders 
(DATAMARS, PetLink, and Youngstown, USA) to ensure identification in the IntelliCages. 
After weaning, the mice were kept in groups of up to 10 separated in according to gender and 
genotype. All the mice had daily injections of BrdU (Bromodeoxyuridine, 50mg/kg) for three 
consecutive days for 4 weeks before the mice were euthanized. The procedure had been 
approved by the Gothenburg committee of the Swedish Animal Welfare Agency (30/2008) [4, 
76]. 
CRT-procedure 
When the mice became 10 days old, both hemispheres were irradiated using a linear accelerator 
(Varian Clinac 600 CD; Radiation Oncology Systems LLC, San Diego, CA, USA) with 4 MV 
nominal photon energy using a dose rate of 2.3 Gy/min at Jubileums-kliniken, Sahlgrenska 
universitetssjukhus in Gothenburg. The total absorbed dose was 8 Gy administered in a single 
dose. The mice were anaesthetized with an intraperitoneal injection of 50 mg/kg tribromethanol 
(Sigma, Stockholm, Sweden) during CRT. The head was covered with one cm tissue equivalent 
material for a more precise CRT dose (dose variation was assessed to be +/- 5 %) passing 
through the brain. The mice were placed in the prone position on an expanded polystyrene bed 
during CRT. The CRT field was 2*2 cm. The whole procedure was completed in 10 minutes.  
Control mice were sedated but not subjected to CRT (figure 8) [4, 76]. 
 
Figure 8 
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Figure 8 CRT procedures. The picture shows an apparatus which was used to investigate 
2.3 Gy per minute. Mice were anesthetized before irradiation. Control mice were only 
anesthetized. 
Procedure Pattern 
See the overview of the procedure pattern below: 
 
 
 
Wt- and C3-/- CRT-treated 
Compared to C3-/- and Wt. 
 
 
 
 
CRT P10 Four months later – thalamus 
and APP-positive cells analysis. 
 
Figure 9 The timeline of the procedure. Mice were exposed to radiation on P10. After 4 
months the mice were sacrificed and the tissue was used for immunohistochemistry. 
Immunohistochemistry 
The mice were deeply anesthetized with sodium pentobarbital 60mg/ml, 2 ml/ 100 g body 
weight i. p. (Pentothal, Electra-box Pharma, Tyresö, Sweden) before being transcardially 
perfused with Histofix (EMD Chemicals Inc., an Affiliate of Mereck KGaA, Darmstadt, 
Germany) in 0.1 M phosphate-buffered saline (PPS) 4 months after CRT. The brains were 
immersion-fixed in Histofix for 24 h at 4oC and then separated into right and left brain parts. 
These were then kept in 0.1 M phosphate-buffer with 30% sucrose solution pH 7. Before further 
processing, the brain stem was cut at the base of the cerebellum. One hemisphere was cut into 
25-μm sagittal sections in a series of 12, using a sliding microtome. To maintain the quality of 
Figure 9 
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the tissue, the sections were stored in a cryo-protection (CPS) solution, containing 25% ethylene 
glycol, 25% glycerine and 50% 0.1 M phosphate-buffer at 4 °C, until staining [4, 76]. 
 
Under immunohistochemistry procedure, all sections were washed at least three times in TBS 
(Tris-buffered saline (TBS, 50 mMTris-HCl in 150 mM NaCl, pH 7.5)) and incubated in 0.6 % 
H2O2 in TBS for 30 minutes for blocking of endogenous peroxidases and for optimal specific 
staining. Next, all sections were incubated in a 10 mM sodium citrate solution, pH 9.0in a 
preheated water path (80oC) under 30 minutes for releasing of cell membranes. The sections 
were then washed  three times in TBS and  incubated in a TBS block solution with 3 % donkey 
serum (Jackson ImmunoResearch Laboratories Inc, West Grove, PA, USA.) and 0.1 % Triton 
X-100 (Merck KGaA, Darmstadt, Germany) for 30 minutes to facilitate antibody binding and 
would be incubated in the same block solution with APP (Amyloid precursor protein – anti 
body against APPs N-terminal), 1:1000 (Rabbit polyclonal anti-APP, Sigma- Aldrich, St. 
Louis, MO, USA.) at 4oC for a whole night. The following day, the sections were washed three 
times in TBS and incubated within block solution containing biotinylated a secondary 
antibodies (donkey anti-rabbit, 1:1000, Jackson ImmunoResearch Laboratories Inc, West 
Grove, PA, USA) for one hour. Again sections were washed with TBS at least three times and 
then incubated in avidin-biotin-peroxidase (10 µl/ml TBS of A and B, Vectastain Elite ABC 
Kit Vector Laboratories, Bulingame, CA, USA.) for one hour to enable binding of avidin-
biotin-peroxidase complex to the secondary antibodies. The sections were then washed up in 
TBS and this time the sections were developed for three minutes in 3, 3’-diaminobenzidine 
adulterated with TBS, H2O2 and NiCl2 to intensify the reaction. Subsequently, the sections were 
rinsed for at least 4 times with lukewarm tap water and then mounted from 0.1 M phosphate 
buffer, pH 7.5, on glass slides (Menzel-Gläser, ThermoScientific, Microscope slides 25*75*1.0 
mm, Mediate Gmbh, Burgdorf, Germany). The sections were left to dry overnight. The next 
day, the glass slides would be cover slipped (X-Tra-Kitt, and Menzel-Gläser cover slips 24*60 
mm, Mediate Gmbh, Burgdorf, Germany) [4, 76]. 
 
Cell counting of APP-positive cells in the thalamus 
The project was based on cell counting and was accomplished by quantifying APP-positive 
cells for the N-terminal throughout the thalamus in all sections containing a clear vision of 
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thalamus. This was accomplished using stereological principles (Stereoinvestigator, 
MicroBrightField, Colchester, VT, USA.). The thalamus area was identified at × 5 
magnification (Using a Leica DM6000 B microscope – Leica microsystems, Wetzlar, 
Germany) with a DIC filter in the stereo Investigator program (MBF Bioscience Inc., Williston, 
VT, USA.). A micro-fire camera (Optronics, Goleta, CA, USA.) was used for visualization. 
All APP-positive cells in the thalamus were counted in every section in the right hemisphere in 
× 20 magnifications, resulting in 5–7 sections per animal (n=7–8). Total volumes were 
calculated according to the Cavalieri principle, using the following formula: V=SA × P × T, 
where V is the total volume, SA is the sum of area measurements, P is the inverse of the 
sampling fraction and T is the section thickness. The total number of cells was obtained by 
multiplying the number of counted cells with the sampling fraction. The structure of the area of 
the thalamus and the APP-positive cells of the thalamus of every mouse was carefully analysed 
[4, 76].  
The thalamus in sagittal cut sections was traced at 5x magnification in the Stereo Investigator 
program (MBF Bioscience Inc., Williston, VT, USA). APP-positive cells for the N-terminal 
within every tracing were counted at 20x magnification for each animal in all groups. 
 
Statistical analysis 
All data from the cell counting and volume measurements were analysed using a two-way 
ANOVA. The results were shown as mean ± standard error of the mean (SEM), with P < 0.05 
considered statically significant. Treatment (control and cranial radio-therapeutic) and 
genotype (wild type and C3-/-) were considered as main effects. Statistical analysis was 
performed using SPSS 21.0 (SPSS, Chicago, IL, USA). 
 
Medical relevance and Ethical considerations 
We hope with our study that if we can alleviate the late effects seen after radiotherapy, we 
would improve the quality of life for children who survive brain cancer. This research program 
used a preclinical setup with a rodent model. Cell cultures were used if possible, but 
unfortunately cell culture as a model can’t replace the animal experiments fully considering the 
important cross-talk that happens in the body after a CRT-induced injury. All mice experiments 
were approved by the local committee of the Swedish Animals Welfare Agency (30/2008). 
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Results 
There was marked difference in the expression of APP+ cells between different regions in the 
brain of the mouse. APP-positive cells in the thalamus vary in density with maximum number 
in the superior – frontal plane and less in the inferior - posterior plane. It is also accumulated 
in some parts of the thalamus (LP, LD and RT superior portion) which have several functions, 
while in the other parts APP+ dots are missing partially or completely.  
The APP+ N-terminal staining displayed clear, dark oval shaped dots (figure 10). It has 
been shown that the distribution of APP throughout the thalamus is altered by CRT in Wt mice 
[116]. In this study, wild type and C3-/- mice were treated with CRT (8 Gy) at postnatal day 10. 
At the age of four months the mice were sacrificed and the thalamus volume and APP 
expression was further analysed. APP (N-terminal) expression was analysed using stereological 
procedures following CRT in the thalamus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 a representative microphotograph of the thalamus taken at 20x magnification. The 
N-terminal of APP is seen as black oval shaped dots (   ). APP cells from Wt Female mouse 
after CRT-treatment. All APP-positive cells were quantified throughout the entire thalamus. 
 
 
 
Figure 10 
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Figure 11 shows different result of thalamus volume, APP-positive cells and APP density 4 
months after CRT between the genotypes. A: show the volume of the entire thalamus. B: show 
the total expression of APP. C: shown the density of APP-positive cells/mm3. All data shown 
as mean ± S.E.M. n=8 per group. 
 
Change of the thalamus before and after CRT: The volume of the thalamus was estimated 
at 4 months after CRT for these different groups; Wt, CRT-Wt, C3-/- and CRT-C3-/-. There was 
a significant lack of growth in the thalamic structure following CRT.  There was no significant 
difference between the genotypes. Four months after CRT the volume of the thalamus was 
significantly reduced (p=0.016). The volume was reduced by 10.6 % in the Wt-mice and 17.3 % 
in the C3-deficient mice. Neither the total number of APP-positive cells nor the density of APP 
in the thalamus was affected by genotype or CRT. The APP-positive cells were expressed to 
the same amount in irradiated and controls for wild type and C3-/- mice. There was however a 
slight increase of APP expression following CRT. The increase in density was 9.4% for the Wt 
mice and 29.8 % for the C3-deficient mice. A higher number of animals per group would be 
necessary to distinguish if there is a difference or not. 
  
      A                                                   B                                               C 
Figure 11 
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Discussion 
 
This study aimed to investigate how inflammatory modulation before and after CRT influence 
cognitive functions and learning in young mice. It has been shown that C3-/- mice have 
improved learning and memory following cranial radiotherapy compared to Wt mice. This 
difference was however not due to a protection in the hippocampus. Hence, we assessed the 
effects of C3-/- on the volumes of the thalamus and also the APP expression in this area. Here 
we demonstrated that Wt and C3-/- mice have a reduced thalamic volume 4 months after a single 
dose of CRT at the age of 10 days. This lack of growth could presumably have a high impact 
on the cognitive decline seen after cranial radio-therapy in childhood. It has been demonstrated 
that anti-inflammatory treatment can improve some of the adverse side effects seen after CRT, 
such as memory and learning [5, 7, 76, 117]. The complement system is an important mediator 
of the CRT-induced inflammation but it doesn’t affect the change in the volume of thalamus 
after CRT. In this study, the volume of the thalamus was affected 4 months after CRT in the 
developing brain. These results indicate disruptions in the growth of the thalamus due to cell 
death, decreased cellular proliferation etc. caused by CRT. It has been shown that other brain 
regions are highly affected and have less growth after CRT [118]. It has also been shown that 
CRT limits the CNS capability to regenerate, for example in hippocampus [119]. In this study, 
cells of the thalamus expressing APP tend to be unaffected or slightly modulated. Since the 
entire volume of thalamus is affected it would be interesting to quantify the proportion of the 
different cell types present in this region. This is out of the scope in this study but it has been 
shown that neurogenesis, oligogenesis and angiogenesis can be affected by several pathologic 
disturbances such as CRT [4, 120, 121]. 
This study suggests that the APP-positive cells of thalamus in mice can resist the effects of CRT 
at this moderate dose (8 Gy). It is still unclear what role of the APP positive cells have in the 
thalamus and if there is a link between the decreases of sAPPα/β in CSF seen in patients. There 
are however preliminary results that the APP expression investigated in this study is located to 
astrocytes. Further investigations are needed to find out why the N-terminal of APP is located 
in the nucleus of astrocytes and the potential influence it has on the late effects after cranial 
radiotherapy. A clinically adapted dose of 8 Gy to the brains of juvenile mice has been shown 
to induce late side effects and can profoundly diminished neurogenesis and disturbed growth 
of the granule cells layer in the hippocampus [118, 122]. Paediatric brain tumours are planned 
with a higher dose of CRT, even up to 55 Gy to the malignant tissue. A CRT dose of 8 Gy, 
which correspond to 18 Gy when allocate 2 Gy fractions, corresponds to what the healthy tissue 
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surrounding the brain tumour receives [123, 124]. Therefore, this model is a good method to 
study the late effects on the healthy brain tissue.  
Mice that lack C3 used in former study have been shown to have better circumstances for 
hippocampal growth during the subacute phase (7 days after CRT) and improved learning 
months after CRT [76]. This improvement in learning was not due to a long term protection in 
the hippocampus. Moreover, the results from this study could not demonstrate a protection in 
the thalamic region. Nevertheless, C3 deficient mice are protected from CRT-induced learning 
problems indicating the important role of the microenvironment in this kind of injury. Many 
anti-inflammatory drugs could be using for this purpose. Cortisone, estradiol and androgen 
therapy could have neuro-protective features and can influence the functions of hippocampus 
[125-128]. 
This thesis reviews recent insight into the diverse types and function of APP and the cleaving 
mechanism in both normal physiology and pathology, especially the relation to higher cognitive 
functions and thereby synaptic plasticity. It would be intriguing to further develop this research, 
and reveal the secret of APP mechanisms. In this study, the effect of C3 deficiency on the 
volume of the thalamus was affected but the amount of APP-positive cells in the thalamus 4 
months after CRT was unaffected. The CRT-induced lack of growth in thalamus is however a 
new finding and increase the understanding of the cognitive decline in a better manner due to 
its important role in connecting the different brain regions but also its role in memory and 
learning. Furthermore, another study has shown that the APP protein levels was increased in 
the thalamus after CRT and could be linked to the decrease of sAPPα/β seen in cerebrospinal 
fluid in patients following prophylactic radiotherapy [7]. N-terminal APP is normally greatly 
expressed in the anterior part of the thalamus and most part of the medial regions and it has the 
special relation to the hippocampus and cortex. These connections are associated with memory 
and therefore to both learning and cognition [129]. The thalamic nuclei and their connections 
to the cortex and hippocampus are associated with most of inputs and outputs, so called drivers 
and modulators responsible for attention, awareness, memory and language [130-132].  
In summary, this study has shown that there is a trend toward an increase of APP expression 
and smaller thalamic volume following CRT. The increase was 9.4 % for the Wt mice and 
27.3 % for the C3 deficient mice; however the density of APP-positive cells/mm3 was not 
significant. A higher number of animals per group are needed to elucidate if that is the case. It 
is however a possibility that the growing thalamus devoid of physiologic active complement 
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component (C3) has a better opportunity to recover. A lot of research focused on how to avoid 
the late effects of CRT. This is important with the increasing number of long term survivors 
seen in today’s society. With a better understanding of the pathophysiology of brain tumours, 
consequences of therapy, influence of age and gender, it might be possible to find better 
therapeutic strategies to improve the quality of life later on. We hope that further research will 
elucidate how the thalamus and APP could influence the long term side effects after CRT. We 
can so far only speculate whether APP expression in the thalamus has a protective role in the 
brain in general or if it has a mechanism of compensation for cell loss and affected neurogenesis 
after cranial CRT. Collectively, this study and a part of Kalm et al. studies cover a broad field 
of research on CRT effects on normal and tumours tissues. These studies review novel insight 
into the diverse function of CRT and its long term side effects. Significantly, the decline in 
volume of the thalamus after CRT in juvenile mice cannot alone be associated with cognitive 
impairment, but can be correlated with adverse long term side effect together with injuries in 
other brain regions caused by CRT.  
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